BI 409306

Drug Profile

BI 409306

Alternative Names: BI-409306; SUB 166499

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Neuropsychotherapeutics
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Schizophrenia
  • No development reported Cognition disorders

Most Recent Events

  • 01 Oct 2016 Boehringer Ingelheim completes a phase I drug interaction trial in Healthy volunteers in Germany (NCT02853136)
  • 01 Aug 2016 Boehringer Ingelheim initiates a phase I drug interaction trial in Healthy volunteers in Germany (NCT02853136)
  • 29 Jul 2016 Boehringer Ingelheim plans a phase I drug interaction trial in Healthy volunteers in Germany (NCT02853136)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top